Bio-Techne

Merck KGaA Acquires Bio-Techne in a major consolidation within the life sciences sector, establishing a definitive agreement to purchase the Minneapolis-based provider of life science tools for US$73 per share in cash. This transaction equates to an enterprise value of approximately US$11.3 billion (EUR 9.9 billion), representing a substantial 36% premium over Bio-Techne’s one-month volume-weighted average trading price. The acquisition targets high-growth, next-generation markets, strengthening the combined entity's position across the entire life science value chain from initial discovery through commercial manufacturing. Investors can track related market updates on the NASDAQ Exchange. The integration leverages highly complementary portfolios to serve laboratory clients and biopharmaceutical manufacturers navigating increasingly complex workflows. Merck intends to utilize its global scale, manufacturing excellence, and established infrastructure to unlock broader geographic and omnichannel access for Bio-Techne’s specialized offerings. This alignment directly advances the long-term strategic agenda of the Merck Group to prioritize high-growth value drivers and platformed capabilities through disciplined M&A. Leadership from both organizations emphasized the operational and strategic benefits for stakeholders, customers, and global workforces. Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck, noted that Bio-Techne represents an outstanding strategic fit that bridges critical product lines from research labs to production suites. Kim Kelderman, President and CEO of Bio-Techne, stated that the transaction validates the enduring value built by their team over 50 years and provides the necessary scale to deepen their scientific impact globally. Financial Implications and Synergy Timelines as Merck Acquires Bio-Techne Financially, the planned transaction is structured to be immediately accretive to sales growth and EBITDA pre-margin for both the Life Science business unit and the overall Merck Group post-closing. Senior management expects the transaction to become EPS pre-accretive by the third year following the official closing date. Furthermore, Merck projects annualized cost synergies of approximately EUR 140 million, which are anticipated to be fully realized by year 3 after closing, backed by a disciplined integration roadmap that maintains business continuity. The technological assets acquired will significantly expand Merck's existing Discovery Solutions, Advanced Solutions, and Process Solutions divisions. Bio-Techne brings a robust portfolio of recombinant proteins, cytokines, antibodies, and immunoassay kits alongside its ProteinSimple automated protein detection instruments and RNAscope spatial biology technologies. Furthermore, the transaction includes Bio-Techne's 19.9% stake in Wilson Wolf Corporation, a manufacturer of G-Rex cell culture devices, with a forward contract structured to acquire full ownership immediately after calendar year 2027. Technical specifications regarding these reagents and workflows are accessible via the Bio-Techne Portal. From an organizational standpoint, the combination unites two large-scale workforces across North America, Europe, and the Asia-Pacific region. Bio-Techne brings over 3,000 global employees across 34 locations and 15 manufacturing facilities into Merck's network, which already features 14,000 employees in the United States alone. This expansion builds upon Merck's historic US$35 billion inorganic investments in the U.S., which includes the integrations of Millipore in 2010, Sigma-Aldrich in 2015, Versum in 2019, and SpringWorks Therapeutics in 2025. Execution Parameters, Funding Mechanics, and Advisors for the Merger To fund the US$11.3 billion enterprise value transaction, Merck will utilize a balanced combination of existing cash on hand and proceeds generated from new debt issuance. The corporate financial strategy explicitly guarantees the preservation of Merck's strong investment-grade credit rating. The merger agreement has received formal approval from Bio-Techne’s Board of Directors and Merck’s internal corporate bodies, with the definitive closing projected for late 2026 or early 2027, pending shareholder and regulatory approvals. Transaction advisory services are being provided by Guggenheim Securities and J.P. Morgan. Transaction Core Valuation parameters Metric SpecificationValue Metric DataTarget EntityBio-Techne Corporation (NASDAQ: TECH)Acquiring EntityMerck KGaAPer Share Purchase ValueUS$73.00 (All-Cash Structure)Enterprise Value (USD)US$11.3 BillionEnterprise Value (EUR)EUR 9.9 BillionTrading Premium Baseline36% over 1-month volume weighted average priceLead Transaction AdvisorsGuggenheim Securities, J.P. MorganTarget Closing WindowLate 2026 to Early 2027 Projected Financial Synergies and Accretion Target Timelines Milestone TypeExpected Financial OutcomeImmediate Post-Closing AccretionPositive impact on Sales Growth & EBITDA pre marginEPS Pre Accretion TargetFully accretive by Year 3 post-closingAnnualized Cost SynergiesApproximately EUR 140 MillionSynergy Realization Target100% integration realization by Year 3 post-closingFunding Strategy ProfileCombined Cash on Hand and New Debt IssuanceCorporate Credit MandatePreservation of a strong investment-grade credit rating Bio-Techne Operational Asset Profile Asset CategoryReported Metrics (FY2025 Baseline)Annual Net Sales> US$1.2 Billion (Fiscal Year 2025)Total Global HeadcountMore than 3,000 employeesU.S. Headcount ConcentrationApproximately 2,300 employeesGlobal Operational Footprint34 distinct locationsManufacturing Infrastructure15 facilities (U.S., Canada, UK, Switzerland, China)Core Workflow TechnologiesProteinSimple instruments, RNAscope hybridization toolsWilson Wolf Equity Position19.9% stake (100% forward contract execution post-calendar 2027) Chronological History of Merck M&A Investments in the United States Acquisition YearAcquired Target EntityPrimary Strategic Workflow FocusTotal Portfolio Capitalization2010MilliporeFiltration & Bioprocess InfrastructurePart of cumulative US$35 Billion pool2015Sigma-AldrichReagents, Chemicals, Lab ConsumablesPart of cumulative US$35 Billion pool2019VersumAdvanced Electronics & SemiconductorsPart of cumulative US$35 Billion pool2025SpringWorks TherapeuticsAdvanced Therapeutics Portfolio expansionPart of cumulative US$35 Billion pool2026/2027Bio-Techne CorporationMulti-omics, Spatial Biology, ProteomicsUS$11.3 Billion Enterprise Value

Tag: Bio-Techne

Merck KGaA Acquires Bio-Techne to Advance ProteinSimple and RNAscope Workflows in $11.3 Billion Deal

Areas Covered

Discover More

Merck KGaA Acquires Bio-Techne to Advance ProteinSimple and RNAscope Workflows in $11.3 Billion Deal

Pfizer Inc. Announces Milestone as FDA Approves Pfizer’s Ibrance Regimen for Advanced Breast Cancer Frontline Maintenance

Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonist Therapies

Gilead Trodelvy European Commission Approval Marks Historic First-Line Breast Cancer Advance

Pfizer Sigvotatug Vedotin Phase 3 Topline Results Released for Lung Cancer

AbbVie to Acquire Apogee Therapeutics to Advance Zumilokibart (APG777) in $10.9 Billion Portfolio Expansion